PharmaHealthcareBioTechManufacturing

Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

Life Science Connect
Life Science Connect•Mar 23, 2026

Why It Matters

Legend’s ability to scale a $1 billion‑plus CAR‑T product while maintaining biotech agility sets a benchmark for commercializing complex therapies and directly impacts investor confidence and patient access in a rapidly evolving oncology market.

Key Takeaways

  • •Legend’s CAR‑T therapy Carvykti generates $555M Q4 sales.
  • •Carvykti treated over 10,000 multiple myeloma patients worldwide.
  • •Alan Bash leverages big‑pharma and biotech experience for growth.
  • •Competition looming; Legend must expand access and pipeline.
  • •Cash‑rich, mid‑size model offers agility and commercial scale.

Summary

In a Business of Biotech interview, Legend Biotech’s President Alan Bash discusses the commercial trajectory of Carvykti, the J&J‑partnered CAR‑T therapy for multiple myeloma that received FDA approval in 2022 and now generates blockbuster revenues. Bash highlights the product’s Q4 2025 sales of $555 million and the milestone of treating more than 10,000 patients, positioning Carvykti as the top‑selling CAR‑T across all indications.

The conversation delves into the strategic levers behind that success: a robust partnership with Johnson & Johnson, aggressive market‑access initiatives, and a cash‑rich balance sheet of roughly $900 million that fuels both scale‑up and pipeline development. Bash warns that new CAR‑T candidates are approaching the market, making patient‑access programs and next‑generation indications critical to sustain leadership.

Bash’s background—22 years at Bristol‑Myers Squibb, CEO roles at Checkmate and Zeal Bio—illustrates a blend of big‑pharma discipline and biotech agility. He describes Legend as the “Goldilocks” company: large enough to support an approved therapy and pipeline, yet small enough to make rapid, science‑driven decisions. His anecdotes about navigating cash runway at small biotechs and the swift Regeneron acquisition of Checkmate underscore the importance of financial discipline.

For investors and industry observers, Legend’s model signals that mid‑size, publicly traded biopharma can dominate high‑price, high‑complexity modalities while retaining the flexibility of a startup. Defending Carvykti’s market share against emerging competitors will require continued innovation, expanded indications, and sustained payer engagement, making the company a bellwether for the next wave of CAR‑T commercialization.

Original Description

On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ZielBio, and his strategy for growing Carvykti's patient footprint and facing new competitors in the market.
Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:

Comments

Want to join the conversation?

Loading comments...